After-Hours Stock Movers 05/18: (ABUS) (DAC) (BIDU) Higher; (BLPH) (GMDA) (GOSS) Lower (more...)

Baidu (BIDU) PT Raised to $145 at KeyBanc As the Company Begins Recovery from COVID-19

KeyBanc analyst Hans Chung raised the price target on Baidu (NASDAQ: BIDU) to $145.00 (from $136.00) while maintaining a Overweight rating.Though ad demand for offline related business has not fully recovered from the COVID-19 pandemic, recovery is tracking ahead of expectations.

1Q's Total... More

Bellerophon Therapeutics (BLPH) Prices 3.077M Share Common Offering at $13/Sh; Announces Pricing of 1.15M Registered Direct Offering

Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) today announced the pricing of offerings for an aggregate of 3,076,923 shares of its common stock at a public offering price of $13.00 per share (the Offerings). The Offerings consisted of an underwritten public offering (the Underwritten Offering) of 1,923,077 shares and a registered direct offering (the Direct Offering) of 1,153,846 shares to an institutional investor... More

Mizuho Securities Reiterates Buy Rating on Baidu (BIDU) Following 1Q

Mizuho Securities analyst James Lee reiterated a Buy rating and $175.00 price target on Baidu (NASDAQ: BIDU) following the company's 1Q. Baidu beat core operating profit estimates by >60% on strong cost controls and provided encouraging signs of near-term revenue recovery.

During revenue uncertainty, management... More

Gossamer Bio Inc. (GOSS) Prices 9.433M Share Common Offering at $13.25/Sh; Announces Pricing of $200M Convertible Senior Notes Due 2027

Gossamer Bio, Inc. (NASDAQ: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the pricing of its underwritten public offering of 9,433,963 shares of its common stock at a price to the public of $13.25 per share and the pricing of $200.0 million aggregate principal amount of its 5.00% convertible senior notes due 2027. The aggregate gross proceeds to Gossamer from the offerings, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $325.0 million.

Gossamer also... More

Gamida Cell Ltd. (GMDA) Prices 13.334M Share Common Offering at $4.50/Sh

Gamida Cell Ltd. (NASDAQ: GMDA) today announced the pricing of an underwritten public offering of 13,333,334 ordinary shares at a public offering price of $4.50 per share for aggregate gross proceeds of approximately $60 million, before deducting underwriting discounts and commissions and estimated offering expenses. In addition,... More

Moderna (MRNA) Prices 17.6M Share Common Offering at $76/Sh

Moderna, Inc. (NASDAQ: MRNA) today announced the pricing of an underwritten public offering of 17,600,000 shares of common stock at a public offering price of $76.00 per share, before underwriting discounts and commissions. In addition, Moderna has granted the underwriters a 30-day option to purchase up to... More

Clovis Oncology (CLVS) Prices 11.09M Share Common Offering at $8.05/Sh

Clovis Oncology, Inc. (NASDAQ: CLVS) announced today the pricing of 11,090,000 shares of its common stock in an underwritten public offering at a price to the public of $8.05 per share, before underwriting discounts and commissions. Clovis Oncology also granted to the underwriters a 30-day option... More